Catalyst catapults on FDA 'breakthrough' for rare autoimmune disease drug

Shares of Catalyst Pharmaceutical Partners catapulted 76% on 27 August on news the FDA granted breakthrough therapy designation to the Florida specialty pharma's experimental drug Firdapse (amifampridine phosphate), which is under investigation to treat symptoms associated with Lambert-Eaton Myasthenic syndrome (LEMS), a rare autoimmune disease, which results in muscle weakness, particularly in the legs and trunk.

Shares of Catalyst Pharmaceutical Partners catapulted 76% on 27 August on news the FDA granted breakthrough therapy designation to the Florida specialty pharma's experimental drug Firdapse (amifampridine phosphate), which is under investigation to treat symptoms associated with Lambert-Eaton Myasthenic syndrome (LEMS), a rare autoimmune disease, which results in muscle weakness, particularly in the legs and trunk.

The stock closed at $2.01, a gain of 59 cents, or about 42%.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category